The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model

Chemotherapy-resistant osteosarcoma is a recalcitrant disease. It is a frequent cause of death to the patients who are usually adolescent or young adults. The goal of the present study was to determine the efficacy of the combination of olaratumab (OLA), doxorubicin (DOX), and cisplatinum (CDDP) on...

詳細記述

保存先:
書誌詳細
出版年:Transl Oncol
主要な著者: Higuchi, Takashi, Sugisawa, Norihiko, Miyake, Kentaro, Oshiro, Hiromichi, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.
フォーマット: Artigo
言語:Inglês
出版事項: Neoplasia Press 2019
主題:
Original article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624322/
https://ncbi.nlm.nih.gov/pubmed/31299622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.06.002
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料